Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.

MLA

Roskell NS, et al. “Annualized Relapse Rate of First-Line Treatments for Multiple Sclerosis: A Meta-Analysis, Including Indirect Comparisons versus Fingolimod.” Current Medical Research & Opinion, vol. 28, no. 5, May 2012, pp. 767–80. EBSCOhost, https://doi.org/10.1185/03007995.2012.681637.

APA

Roskell NS, Zimovetz EA, Rycroft CE, Eckert BJ, & Tyas DA. (2012). Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod. Current Medical Research & Opinion, 28(5), 767–780. https://doi.org/10.1185/03007995.2012.681637

Chicago

Roskell NS, Zimovetz EA, Rycroft CE, Eckert BJ, and Tyas DA. 2012. “Annualized Relapse Rate of First-Line Treatments for Multiple Sclerosis: A Meta-Analysis, Including Indirect Comparisons versus Fingolimod.” Current Medical Research & Opinion 28 (5): 767–80. doi:10.1185/03007995.2012.681637.